Fibrinolytic therapy of St. Jude valve thrombosis under guidance of digital cinefluoroscopy

Thrombosis of St. Jude medical cardiac valve in the mitral position.

T he St. Jude medical cardiac valve prosthesis is presently undergoing clinical hiaL In dfm trials demonstrated superior hernodynamic properties compared with other clinicaIly available d a c valve pros

Fibrinolytic Therapy of Coronary Thrombosis.

Combined warfarin and antiplatelet therapy after St. Jude Medical valve replacement for mitral valve disease.

OBJECTIVES The clinical effect of combined warfarin and antiplatelet therapy on the incidence of stroke and postoperative complications after mitral (plus aortic) valve replacement was studied and compared with that observed with warfarin therapy alone. BACKGROUND It has been reported that combined warfarin and antiplatelet therapy may be effective but may be associated with an increased hemo...

Long-term outcomes after St. Jude Medical mechanical valve implantation.

patient-year), major bleeding events (1.0%/patient-year), and aortic valve reoperation (0.26%/patient-year). They also reported that valve-related death was the most common cause of death (26.8%) and that the rates of freedom from valve-related death were 96.2%, 92.7%, 88.8%, and 86.6% at 5, 10, 15, and 20 years, respectively. These results compare favorably with the findings of previous report...

Flow-induced platelet activation in a St. Jude mechanical heart valve, a trileaflet polymeric heart valve, and a St. Jude tissue valve.

Polymer heart valves have been under investigation since the 1960s, but their success has been hampered by an overall lack of durability mainly due to calcification of the leaflets and a relatively high rate of thromboembolic complications. A new polymer (Quatromer) trileaflet design was tested for its thrombogenic potential and was compared to that of existing prosthetic heart valves routinely...